Protocol for intralesional injection of bevacizumab for severe recurrent respiratory papillomatosis
DOI:
https://doi.org/10.34631/sporl.2212Keywords:
Respiratory Papillomatosis, Bevacizumab, HPV, Laryngology, SurgeryAbstract
Introduction: Recurrent respiratory papillomatosis (RRP) is a chronic condition associated with the growth of papillomas in the airways, with impaired voice and respiratory quality. Recent studies have shown that intralesional injection of bevacizumab increases the interval between surgeries, improves quality of life, and has a virtually zero risk of complications.
Objectives: To establish a protocol for intralesional application of bevacizumab in patients with severe RRP.
Materials and Methods: The search included the PUBMED and Cochrane databases. A review of relevant medical literature was conducted.
Results: The protocol consists of four distinct phases: selection of patients with severe RRP requiring adjuvant therapy and obtaining informed consent, staging and assessment of preoperative disease burden, implementation of adjuvant treatment with intralesional bevacizumab as outlined, and follow-up and efficacy criteria.
Conclusions: For the treatment of severe RRP, this standardized technique provides a systematic method for injecting bevacizumab intralesionally.
References
Fortes HR, von Ranke FM, Escuissato DL, Araujo Neto CA, Zanetti G, Hochhegger B. et al. Recurrent respiratory papillomatosis: A state-of-the-art review. Respir Med. 2017 May:126:116-121. doi: 10.1016/j.rmed.2017.03.030.
Benedict JJ, Derkay CS. Recurrent respiratory papillomatosis: A 2020 perspective. Laryngoscope Investig Otolaryngol. 2021 Mar 13;6(2):340-345. doi: 10.1002/lio2.545.
San Giorgi MRM, Aaltonen LM, Rihkanen H, Tjon Pian Gi REA, van der Laan BFAM, Hoekstra-Weebers JEHM. et al. Quality of life of patients with recurrent respiratory papillomatosis. Laryngoscope. 2017 Aug;127(8):1826-1831. doi: 10.1002/lary.26413.
Benedict PA, Ruiz R, Yoo M, Verma A, Ahmed OH, Wang B. et al. Laryngeal distribution of recurrent respiratory papillomatosis in a previously untreated cohort. Laryngoscope. 2018 Jan;128(1):138-143. doi: 10.1002/lary.26742.
Derkay CS, Malis DJ, Zalzal G, Wiatrak BJ, Kashima HK, Coltrera MD. A staging system for assessing severity of disease and response to therapy in recurrent respiratory papillomatosis. Laryngoscope. 1998 Jun;108(6):935-7. doi: 10.1097/00005537-199806000-00026.
Derkay CS, Hester RP, Burke B, Carron J, Lawson L. Analysis of a staging assessment system for prediction of surgical interval in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol. 2004 Dec;68(12):1493-8. doi: 10.1016/j.ijporl.2004.06.007.
Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope. 2008 Jul;118(7):1236-47. doi: 10.1097/MLG.0b013e31816a7135.
Zeleník K, Komínek P, Staníková L, Formánek M. Local bevacizumab treatment of juvenile-onset respiratory papillomatosis might induce multiple tracheal pyogenic granulomas. Laryngoscope. 2021 Feb;131(2):E518-E520. doi: 10.1002/lary.28928.
Sidell DR, Nassar M, Cotton RT, Zeitels SM, de Alarcon A. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2014 Mar;123(3):214-21. doi: 10.1177/0003489414522977.
Zeitels SM, Barbu AM, Landau-Zemer T, Lopez-Guerra G, Burns JA, Friedman AD. et al. Local injection of bevacizumab (avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. Ann Otol Rhinol Laryngol. 2011 Oct;120(10):627-34. doi: 10.1177/000348941112001001.
Best SR, Friedman AD, Landau-Zemer T, Barbu AM, Burns JA, Freeman MW. et al. Safety and dosing of bevacizumab (avastin) for the treatment of recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2012 Sep;121(9):587-93. doi: 10.1177/000348941212100905.
Pogoda L, Ziylan F, Smeeing DPJ, Dikkers FG, Rinkel RNPM. Bevacizumab as treatment option for recurrent respiratory papillomatosis: a systematic review. Eur Arch Otorhinolaryngol. 2022 Sep;279(9):4229-4240. doi: 10.1007/s00405-022-07388-6.
Woo SH, Chung P, Lee SJ. Treatment of recurrent respiratory papillomatosis using laser and available adjuvant therapies. Med Lasers [Internet] 2020; 9(2): 126-133 Available from: https://doi.org/10.25289/ML.2020.9.2.126.
Coordes A, Grund D, Mainka A, Olze H, Hanitsch L, von Bernuth H. et al. Recurrent laryngeal papillomatosis. HNO. 2023 Feb;71(2):77-82. doi: 10.1007/s00106-022-01250-1.
Infarmed. Relatório de avaliação prévia do medicamento para uso humano em meio hospitalar; DCI – Bevacizumab. [Internet]. Lisboa: INFARMED Autoridade Nacional do Medicamento e Produtos de Saúde, I.P.; 2018. Available from: https://www.infarmed.pt/documents/15786/1424140/Relatório+público+de+avaliação+de+Avastin+%28bevacizumab%29+2018/6c14975e-768b-498f-8403-d266e9a4df73.
Nagel S, Busch C, Blankenburg T, Schutte W. Treatment of respiratory papillomatosis–a case report on systemic treatment with bevacizumab. Pneumologie. 2009 Jul;63(7):387-9. doi: 10.1055/s-0029-1214714.
Zeitels SM, Lopez-Guerra G, Burns JA, Lutch M, Friedman AM, Hillman RE. Microlaryngoscopic and office-based injection of bevacizumab (Avastin) to enhance 532-nm pulsed KTP laser treatment of glottal papillomatosis. Ann Otol Rhinol Laryngol Suppl. 2009 Sep:201:1-13. doi: 10.1177/000348940911800901.
Zeitels SM, Barbu AM, Landau-Zemer T, Lopez-Guerra G, Burns JA, Friedman AD. et al. Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. Ann Otol Rhinol Laryngol. 2011 Oct;120(10):627-34. doi: 10.1177/000348941112001001.
Tasca RA, Clarke RW. Recurrent respiratory papillomatosis Arch Dis Child. 2006 Aug;91(8):689-91. doi: 10.1136/adc.2005.090514.
Goon P, Sauzet O, Schuermann M, Oppel F, Shao S, Scholtz LU. et al. Recurrent Respiratory Papillomatosis (RRP)-Meta-analyses on the use of the HPV vaccine as adjuvant therapy. NPJ Vaccines. 2023 Apr 1;8(1):49. doi: 10.1038/s41541-023-00644-8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Portuguese Journal of Otorhinolaryngology and Head and Neck Surgery
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
